Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model
Anti-GQ1b ganglioside antibodies are the serological hallmark of the Miller Fisher syndrome (MFS) variant of the paralytic neuropathy, Guillain–Barré syndrome, and are believed to be the principal pathogenic mediators of the disease. In support of this, we previously showed in an in vitro mouse model of MFS that anti-GQ1b antibodies were able to bind and disrupt presynaptic motor nerve terminals at the neuromuscular junction (NMJ) as one of their target sites, thereby causing muscle paralysis.
cut and paste the following link:
http://brain.oxfordjournals.org/cgi/content/short/131/5/1197
You must be logged in to reply to this topic.
© Copyright GBS|CIDP Foundation International Forums.
Use of this Web site constitutes acceptance of our Terms of Use and Privacy Policy.
GBS|CIDP Foundation International is a 501(c)3 tax-exempt organization.
Cookie | Duration | Description |
---|---|---|
CONSENT | 16 years 6 months 14 days 2 hours 6 minutes | No description |
cookielawinfo-checkbox-functional | 1 year | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-others | 1 year | No description |